Compounds for the treatment of BRAF-associated diseases and disorders

US11414404B2 · kind B2 · utility

Assignee

• Array BioPharma, Inc. · US

Inventors

• Patrick Barbour · Boulder, US
• Katie Keaton BROWN · Niwot, US
• Adam Cook · Boulder, US
• Erik James Hicken · Boulder, US
• Dean Russell Kahn · Boulder, US
• Ellen Laird · Longmont, US
• Andrew T. Metcalf · Boulder, US
• David A. Moreno · Boulder, US
• Bradley J. Newhouse · Broomfield, US
• Spencer Pajk · Boulder, US
• Brett Prigaro · Broomfield, US
• Li Ren · Superior, US
• Eugene Tarlton · Superior, US

Key dates

• Filing date: Jun 24, 2020
• Grant date: Aug 16, 2022
• Expiry date: Jun 24, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.